Post Profile

Novartis challenges Pfizer with strong breast cancer drug data

COPENHAGEN (Reuters) - An experimental Novartis pill given with an older drug kept advanced breast cancer in check far longer than standard treatment alone, putting it on track to challenge Pfizer's blockbuster Ibrance, data showed on Saturday.
read more


Related Posts

Business Briefing: Pfizer Breast Cancer Drug Wins Federal Approval

Health : NYTimes: Health

The Food and Drug Administration approved Ibrance for women who have tumors that do not contain a protein known as HER-2.

Breast Cancer Patients Live Nearly Six Months Longer With New Precision Drug Compared To Current Treatment Option

Health : Medical News Today

Data from the Phase III EMILIA study, presented at the European Society for Medical Oncology (ESMO) show that T-DM1 (trastuzumab emtansine) prolongs the lives of patients with advanced HER2-positive breast cancer when compared with ...

FDA Approves New Drug that has Shown Groundbreaking Results in Patients with Estrogen-Receptor Positive Advanced Breast Cancer

Health : Newswise Medical News

FDA has approved IBRANCE (palbociclib), representing a new treatment method to arrest tumor growth in certain advanced breast cancer patients. IBRANCE targets a key family of proteins responsible for cell growth. Results of a phase ...

EMA panel recommends nod for Pfizer's breast cancer drug

Health : Reuters: Health

(Reuters) - U.S. drugmaker Pfizer Inc's breast cancer drug, Ibrance, should be given marketing approval, an advisory committee at the European Medicines Agency recommended.

Pfizer: FDA approves cancer drug

Business & Finance : Business Report

Pfizer’s drug Ibrance was approved for advanced breast cancer by US regulators more than two months ahead of schedule, letting the drugmaker proceed with one of its most promising new blockbusters. ||| PFIZER’S drug Ibrance was appr...


Copyright © 2016 Regator, LLC